An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101
Trial details
- Registry ID
- NCT06867107
- Drugs studied
- SAT-3247
TrialRedline tracks 3 clinical trials sponsored by Satellos Bioscience, Inc.: 3 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101NCT06867107 | SAT-3247 | Recruiting | 2027-09-30Estimated |
| A Study of SAT-3247 to Evaluate the Safety, Tolerability, and Efficacy in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)NCT07872306 | forazapadin | Not yet recruiting | 2028-12-30Estimated |
| Phase 2 Study of SAT-3247 in Pediatric Ambulatory PatientsNCT07287189 | SAT-3247 | Active not recruiting | 2027-03-31Estimated |
Names as written in the registry records.
NCT06867107 · Satellos Bioscience, Inc.
Before: Enrolling by invitation. After: Recruiting.
NCT06867107 · Satellos Bioscience, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Treatment emergent adverse events Description: Incidence, temporal profile, and severity of treatment emergent adverse events (TEAEs) Time frame: 24 months Measure: SAT-3247 effect on fat fraction in biceps brachii Description: Changes from baseline in intramuscular fat fraction in muscle quantitative magnetic resonance (qMR) in biceps brachii following treatment with SAT-3247. Time frame: 24 months. After: Measure: Treatment emergent adverse events Description: Incidence, temporal profile, and severity of treatment emergent adverse events (TEAEs) Time frame: 12 months Measure: SAT-3247 effect on fat fraction in biceps brachii Description: Changes from baseline in intramuscular fat fraction in muscle quantitative magnetic resonance (qMR) in biceps brachii following treatment with SAT-3247. Time frame: 12 months.
NCT07287189 · Satellos Bioscience, Inc.
Before: Recruiting. After: Active not recruiting.
NCT06867107 · Satellos Bioscience, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Treatment emergent adverse events. After: Measure: Treatment emergent adverse events Measure: SAT-3247 effect on fat fraction in biceps brachii.
Before: 10 participants (planned). After: 30 participants (planned).
Before: 30 Aug 2026. After: 30 Sep 2027.
NCT07287189 · Satellos Bioscience, Inc.
Before: Active not recruiting. After: Recruiting.
NCT07287189 · Satellos Bioscience, Inc.
Before: 31 Mar 2026. After: 31 Mar 2027.